Paper324279
Significance of antimicrobial synergism for the outcome of gram negative sepsis.
Klastersky J and 2 others. Am J Med Sci, 1977. Cited by 162 papers, by iCite.
Cite this record
ConductScience Library. Significance of antimicrobial synergism for the outcome of gram negative sepsis. Papers, record 324279. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/324279
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics14
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Amikacin | Major topic |
| Bacterial Infections | Major topic |
| Carbenicillin | Major topic |
| Kanamycin | Major topic |
| Penicillin G | Major topic |
| Blood Chemical Analysis | |
| Clinical Trials as Topic | |
| Drug Evaluation | |
| Drug Synergism | |
| Drug Therapy, Combination | |
| Focal Infection | |
| Humans | |
| Sepsis | |
| Urinary Tract Infections |
Source PubMed
Cited by42
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 162 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 24977667 | Epidemiology and outcome of bacteraemia in neutropenic patients in a single institution from 1991-2012. | Epidemiol Infect | 2015 | https://conductscience.org/library/papers/24977667 | PubMed |
| 22763634 | Combination therapy for treatment of infections with gram-negative bacteria. | Clin Microbiol Rev | 2012 | https://conductscience.org/library/papers/22763634 | PubMed |
| 16033288 | Antifungal combination therapy: clinical potential. | Drugs | 2005 | https://conductscience.org/library/papers/16033288 | PubMed |
| 14996699 | Beta lactam monotherapy versus beta lactam-aminoglycoside combination therapy for sepsis in immunocompetent patients: systematic review and meta-analysis of randomised trials. | BMJ | 2004 | https://conductscience.org/library/papers/14996699 | PubMed |
| 12763980 | Beta lactam monotherapy versus beta lactam-aminoglycoside combination therapy for fever with neutropenia: systematic review and meta-analysis. | BMJ | 2003 | https://conductscience.org/library/papers/12763980 | PubMed |
| 12141969 | Pandrug-resistant Acinetobacter baumannii causing nosocomial infections in a university hospital, Taiwan. | Emerg Infect Dis | 2002 | https://conductscience.org/library/papers/12141969 | PubMed |
| 10461420 | Imipenem-cilastatin versus sulbactam-cefoperazone plus amikacin in the initial treatment of febrile neutropenic cancer patients. | Korean J Intern Med | 1999 | https://conductscience.org/library/papers/10461420 | PubMed |
| 9145838 | Comparative in vitro antimicrobial susceptibilities of nosocomial isolates of Acinetobacter baumannii and synergistic activities of nine antimicrobial combinations. | Antimicrob Agents Chemother | 1997 | https://conductscience.org/library/papers/9145838 | PubMed |
| 9007594 | Postantibiotic effect of ceftriaxone and gentamicin alone and in combination on Klebsiella pneumoniae, Pseudomonas aeruginosa and Streptococcus viridans. | Infection | 1996 | https://conductscience.org/library/papers/9007594 | PubMed |
| 8723449 | Monotherapy with meropenem versus combination therapy with ceftazidime plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer. The International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer and the Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto Infection Program. | Antimicrob Agents Chemother | 1996 | https://conductscience.org/library/papers/8723449 | PubMed |
| 8156272 | Infections in cancer patients: some controversial issues. | Support Care Cancer | 1994 | https://conductscience.org/library/papers/8156272 | PubMed |
| 7399713 | Prediction and significance of synergy between antibiotics used for treatment for gram-negative sepsis. | Infection | 1980 | https://conductscience.org/library/papers/7399713 | PubMed |
| 6792982 | Comparative in vitro synergistic activity of new beta-lactam antimicrobial agents and amikacin against Pseudomonas aeruginosa and Serratia marcescens. | Antimicrob Agents Chemother | 1981 | https://conductscience.org/library/papers/6792982 | PubMed |
| 6780605 | Methodological variation in antibiotic synergy tests against enterococci. | J Clin Microbiol | 1981 | https://conductscience.org/library/papers/6780605 | PubMed |
| 6651276 | Stability of gentamicin, tobramycin, and amikacin in combination with four beta-lactam antibiotics. | Antimicrob Agents Chemother | 1983 | https://conductscience.org/library/papers/6651276 | PubMed |
| 6538773 | In vitro activity of aztreonam in combination with newer beta-lactams and amikacin against multiply resistant gram-negative bacilli. | Antimicrob Agents Chemother | 1984 | https://conductscience.org/library/papers/6538773 | PubMed |
| 6517544 | Synergism at clinically attainable concentrations of aminoglycoside and beta-lactam antibiotics. | Antimicrob Agents Chemother | 1984 | https://conductscience.org/library/papers/6517544 | PubMed |
| 6428310 | In vitro synergistic activities of aminoglycosides and new beta-lactams against multiresistant Pseudomonas aeruginosa. | Antimicrob Agents Chemother | 1984 | https://conductscience.org/library/papers/6428310 | PubMed |
| 6385840 | Correlation of in vitro activities of cephalothin and ceftazidime with their efficacies in the treatment of Staphylococcus aureus endocarditis in rabbits. | Antimicrob Agents Chemother | 1984 | https://conductscience.org/library/papers/6385840 | PubMed |
| 6331297 | Enhanced in vitro bactericidal activity of amikacin or gentamicin combined with three new extended-spectrum cephalosporins against cephalothin-resistant members of the family Enterobacteriaceae. | Antimicrob Agents Chemother | 1984 | https://conductscience.org/library/papers/6331297 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/324279
GET https://conductscience.org/api/papers/v1/324279/cited_by?page=2